247 related articles for article (PubMed ID: 20050824)
1. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
2. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
3. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
McKeage MJ; Baguley BC
Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
[TBL] [Abstract][Full Text] [Related]
5. Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Baguley BC; Siemann DW
Expert Opin Investig Drugs; 2010 Nov; 19(11):1413-25. PubMed ID: 20964495
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).
Jameson MB; Head M
Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1315-26. PubMed ID: 21870897
[TBL] [Abstract][Full Text] [Related]
7. ASA404: update on drug development.
Rehman F; Rustin G
Expert Opin Investig Drugs; 2008 Oct; 17(10):1547-51. PubMed ID: 18808313
[TBL] [Abstract][Full Text] [Related]
8. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.
McKeage MJ
Clin Lung Cancer; 2011 May; 12(3):143-7. PubMed ID: 21663855
[TBL] [Abstract][Full Text] [Related]
10. ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.
Baguley BC; McKeage MJ
Future Oncol; 2010 Oct; 6(10):1537-43. PubMed ID: 21062153
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
Baguley BC
Clin Lung Cancer; 2011 Mar; 12(2):81-6. PubMed ID: 21550553
[TBL] [Abstract][Full Text] [Related]
12. Antivascular agents for non-small-cell lung cancer: current status and future directions.
Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
[TBL] [Abstract][Full Text] [Related]
13. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
14. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
15. Vascular damaging agents.
Patterson DM; Rustin GJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
[TBL] [Abstract][Full Text] [Related]
16. Taking down tumors: vascular disrupting agents entering clinical trials.
O'Hanlon LH
J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
[No Abstract] [Full Text] [Related]
17. Novel agents target existing tumor vasculature.
Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
[No Abstract] [Full Text] [Related]
18. An overview on Vadimezan (DMXAA): The vascular disrupting agent.
Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Samandari-Rad S; Zarghami N
Chem Biol Drug Des; 2018 May; 91(5):996-1006. PubMed ID: 29288534
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
Lorusso PM; Boerner SA; Hunsberger S
J Clin Oncol; 2011 Aug; 29(22):2952-5. PubMed ID: 21709201
[No Abstract] [Full Text] [Related]
20. Vascular-disrupting agents in oncology.
Mita MM; Sargsyan L; Mita AC; Spear M
Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
